Last reviewed · How we verify
Del-desiran (AOC 1001)
Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.
Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism. Used for Hypertriglyceridemia, Cardiovascular risk reduction in patients with elevated triglycerides.
At a glance
| Generic name | Del-desiran (AOC 1001) |
|---|---|
| Sponsor | Avidity Biosciences, Inc. |
| Drug class | Antisense oligonucleotide |
| Target | APOC3 mRNA |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Del-desiran binds to apoC-III mRNA in hepatocytes, triggering degradation of the transcript and reducing circulating apoC-III levels. ApoC-III inhibits lipoprotein lipase and is associated with elevated triglycerides and cardiovascular risk; lowering it improves triglyceride clearance and lipid profiles.
Approved indications
- Hypertriglyceridemia
- Cardiovascular risk reduction in patients with elevated triglycerides
Common side effects
- Injection site reactions
- Transient liver enzyme elevation
- Flu-like symptoms
Key clinical trials
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 (PHASE3)
- Global Study of Del-desiran for the Treatment of DM1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Del-desiran (AOC 1001) CI brief — competitive landscape report
- Del-desiran (AOC 1001) updates RSS · CI watch RSS
- Avidity Biosciences, Inc. portfolio CI